Company news
HemoGenyx Pharmaceuticals PLC news in 2020
HemoGenyx Pharmaceuticals PLC's news releases, calls and decks from 2020, newest first.
Change to Date of General Meeting
December 8, 2020
Posting of Circular
December 2, 2020
Financing Facility of up to £60 Million
November 18, 2020
CDX Development Agreement Further Extension
October 27, 2020
Presentation at the American Society of Hematology
October 19, 2020
SAFE-HEMO-CAR-T Effective against AML in vitro
October 6, 2020
Interim Results for the period ended 30 June 2020
September 30, 2020
Further re. Grant of Options
September 22, 2020
Grant of Options
August 21, 2020
Presentations at Cancer Immunotherapy Symposia
August 14, 2020
CAR-T Agreement with University of Pennsylvania
August 11, 2020
Broker's Research Note
July 31, 2020
Further re Development Agreement
July 13, 2020
US Subsidiary Change of Name
July 10, 2020
New Corporate Video and Investor Webinar
July 6, 2020
Development Agmnt - Autoimmune Disease Treatments
June 26, 2020
Hemogenyx Chairman Receives Tang Prize
June 24, 2020
COVID-19 Project Update
June 15, 2020
Result of AGM and Completion of Placing
June 4, 2020
CDX Development Agreement Extension
June 2, 2020
TR-1: notification of major interest in shares
May 27, 2020
Exercise of Warrants
May 18, 2020
Conditional Placing to raise £2,500,000
May 12, 2020
COVID-19 Project Initiated
April 22, 2020
Approval and Issuance of European Hu-PHEC Patent
April 21, 2020
HEMO-CAR-T cells Effective Against AML in vivo
February 20, 2020
Approval and Issuance of U.S. Hu-PHEC Patent
February 11, 2020
Placing and Subscription to raise £650,000
January 30, 2020
HEMO's CAR-T Cells Effective Against AML in vitro
January 15, 2020